^
    Back
    Association details:
    Biomarker:Chr t(11;14)
    Cancer:Multiple Myeloma
    Regimen: (bortezomib + Venclexta (venetoclax) + dexamethasone injection)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    02/03/2021
    Excerpt:
    Recommendations: Patients who receive second-line therapy: VenVd is a suitable option for patients with t(11;14) who have failed lenalidomide and are sensitive to PIs [I, A], if available….Patients at third and subsequent lines of treatment: Patients with t(11;14), who are refractory to lenalidomide and are PI-sensitive may be treated with VenVd [I, A], if available.
    DOI:
    10.1016/j.annonc.2020.11.014